Acellular pertussis vaccines and pertussis resurgence: Revise or replace?

mBio

Volumn 5, Issue 3, 2014, Pages

  Ausiello, Clara Maria ^a   Cassone, Antonio ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SUBUNIT VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CHEMICAL COMPOSITION; DRUG EFFICACY; DRUG POTENCY; FIMBRIA; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INNATE IMMUNITY; NONHUMAN; PERTUSSIS; PREVENTIVE HEALTH SERVICE; PRIMATE; PRIORITY JOURNAL; RECURRENT INFECTION; VACCINATION; VACCINE FAILURE; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; TH1 CELL; TH17 CELL; WHOOPING COUGH;

ANIMALS; BORDETELLA PERTUSSIS; HUMANS; PERTUSSIS VACCINE; TH1 CELLS; TH17 CELLS; VACCINATION; WHOOPING COUGH;

EID: 84904015646     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01339-14     Document Type: Article

References (34)

1. Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, Wood N, McIntyre P, Marshall H, Guiso N, Keil AD, Lawrence A, Robson J, Hogg G, Lan R. 2014. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg. Infect. Dis. 20: 626-633. http://dx. doi. org/10. 3201/eid2004. 131478.
2. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. 2012. Waning protection after fifth dose of acellular pertussis vaccine in children. N. Engl. J. Med. 367: 1012-1019. http://dx. doi. org/10. 1056/NEJMoa1200850.
3. Clark TA. 2014. Changing pertussis epidemiology: everything old is new again. J. Infect. Dis. 209: 978-981. http://dx. doi. org/10. 1093/infdis/jiu001.
4. Billingsley M. 2012. Pregnant women in UK are offered whooping cough vaccine to protect newborns. BMJ 345: e6594. http://dx. doi. org/10. 1136/bmj. e6594.
5. Plotkin SA. 2014. The pertussis problem. Clin. Infect. Dis. 58: 830-833. http://dx. doi. org/10. 1093/cid/cit934.
6. Burns DL, Meade BD, Messionnier NE. 2014. Pertussis resurgence: perspectives from the Working Group Meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge. J. Infect. Dis. 209: S32-S35. http://dx. doi. org/10. 1093/infdis/jit491.
7. Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V, Cassiday PK, Chiang CS, Dalby T, Fry NK, Gaillard ME, van Gent M, Guiso N, Hallander HO, Harvill ET, He Q, van der Heide HG, Heuvelman K, Hozbor DF, Kamachi K, Karataev GI, Lan R, Lutyłska A, Maharjan RP, Mertsola J, Miyamura T, Octavia S, Preston A, Quail MA, Sintchenko V, Stefanelli P, Tondella ML, Tsang RS, Xu Y, Yao SM, Zhang S, Parkhill J, Mooi FR. 2014. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. mBio 5(2): e01074. http://dx. doi. org/10. 1128/mBio. 01074-14.
8. Cherry JD. 2013. Pertussis: challenges today and for the future. PLoS P a t h o g. 9: e 1 0 0 3 4 1 8. d o i: h t t p://d x. d o i. o r g/1 0. 1 3 7 1/journal. ppat. 1003418.
9. Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, Tozzi AE, Van Damme P. 2011. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 11: 557-570. http://dx. doi. org/10. 1016/S1473-3099(11)70007-X.
10. Chiappini E, Stival A, Galli L, de Martino M. 2013. Pertussis reemergence in the post-vaccination era. BMC Infect. Dis. 13: 151. http://dx. doi. org/10. 1186/1471-2334-13-151.
11. Mills KH, Ross PJ, Allen AC, Wilk MM. 2014. Do we need a new vaccine to control the re-emergence of pertussis? Trends Microbiol. 22: 49-52. http://dx. doi. org/10. 1016/j. tim. 2013. 11. 007.
12. Edwards KM, Berbers GA. 2014. Immune responses to pertussis vaccines and disease. J. Infect. Dis. 209: S10-S15. doi: http://dx. doi. org/10. 1093/infdis/jit560.
13. Cherry JD. 2012. Why do pertussis vaccines fail? Pediatrics 129: 968-970. http://dx. doi. org/10. 1542/peds. 2011-2594.
14. Ausiello CM, Lande R, Urbani F, la Sala A, Stefanelli P, Salmaso S, Mastrantonio P, Cassone A. 1999. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect. Immun. 67: 4064-4071.
15. Fedele G, Bianco M, Ausiello CM. 2013. The virulence factors of Bordetella pertussis: talented modulators of host immune response. Arch. Immunol. Ther. Exp. (Warsz) 61: 445-457. http://dx. doi. org/10. 1007/s00005-013-0242-1.
16. Stenger RM, Meiring HD, Kuipers B, Poelen M, van Gaans-van den Brink JAM, Boog CJP, de Jong APJM, van Els CACM. 2014. Bordetella pertussis proteins dominating the major histocompatibility complex class II-presented epitope repertoire in human monocyte-derived dendritic cells. Clin. Vaccine Immunol. 21: 641-650. http://dx. doi. org/10. 1128/CVI. 00665-13.
17. McGuirk P, McCann C, Mills KH. 2002. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 195: 221-231. http://dx. doi. org/10. 1084/jem. 20011288.
18. Carollo M, Pandolfi E, Tozzi AE, Buisman AM, Mascart F, Ausiello CM. 2014. Humoral and B-cell memory responses in children five years after pertussis acellular vaccine priming. Vaccine 32: 2093-2099. http://dx. doi. org/10. 1016/j. vaccine. 2014. 02. 005.
19. Cassone A, Ausiello CM, Urbani F, Lande R, Giuliano M, La Sala A, Piscitelli A, Salmaso S. 1997. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group. Arch. Pediatr. Adolesc. Med. 151: 283-289. http://dx. doi. org/10. 1001/archpedi. 1997. 02170400069013.
20. Ausiello CM, Urbani F, la Sala A, Lande R, Cassone A. 1997. Vaccineand antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65: 2168-2174.
21. Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, Gothefors L, Oymar K, Miller E, Storsaeter J, Mills KH. 1998. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93: 1-10. http://dx. doi. org/10. 1046/j. 1365-2567. 1998. 00401. x.
22. Smits K, Pottier G, Smet J, Dirix V, Vermeulen F, De Schutter I, Carollo M, Locht C, Ausiello CM, Mascart F. 2013. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination. Vaccine 32: 111-118. http://dx. doi. org/10. 1016/j. vaccine. 2013. 10. 056.
23. Ausiello CM, Lande R, Urbani F, Di Carlo B, Stefanelli P, Salmaso S, Mastrantonio P, Cassone A. 2000. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J. Infect. Dis. 181: 1989-1995. http://dx. doi. org/10. 1086/315509.
24. He Q, Tran Minh NN, Edelman K, Viljanen MK, Arvilommi H, Mertsola J. 1998. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults. Infect. Immun. 66: 3796-3801.
25. Dirix V, Verscheure V, Goetghebuer M, Hainaut AS, Debrie C, Locht F, Mascart F. 2009. Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy. Vaccine 27: 6042-6047. http://dx. doi. org/10. 1016/j. vaccine. 2009. 07. 075.
26. Schure RM, de Rond L, Oztürk K, Hendrikx L, Sanders E, Berbers G, Buisman AM. 2012. Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. PLoS One 7: e41928. http://dx. doi. org/10. 1371/journal. pone. 0041928.
27. Warfel JM, Zimmerman LI, Merkel TJ. 2014. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl. Acad. Sci. U. S. A. 111: 787-792. http://dx. doi. org/10. 1073/pnas. 1314688110.
28. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle EC, McLoughlin RM, Mills KH. 2013. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog. 9: e1003264. http://dx. doi. org/10. 1371/journal. ppat. 1003264.
29. Fedele G, Bianco M, Debrie AS, Locht C, Ausiello CM. 2011. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J. Immunol. 186: 5388-5396. http://dx. doi. org/10. 4049/jimmunol. 1003765.
30. Locht C, Mielcarek N. 2012. New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol. Med. Microbiol. 66: 121-133. http://dx. doi. org/10. 1111/j. 1574-695X. 2012. 00988. x.
31. Robbins JB, Schneerson R, Kubler-Kielb J, Keith JM, Trollfors B, Vinogradov E, Shiloach J. 2014. Toward a new vaccine for pertussis. Proc. Natl. Acad. Sci. U. S. A. 111: 3213-3216. http://dx. doi. org/10. 1073/pnas. 1324149111.
32. Wu Y, Gao Y, Zhu B, Zhou H, Shi Z, Wang J, Wang H, Shao Z. 2014. Antitoxins for diphtheria and tetanus decline more slowly after vaccination with DTwP than with DTaP: a study in a Chinese population. Vaccine 32: 2570-2573. http://dx. doi. org/10. 1016/j. vaccine. 2014. 03. 052.
33. Feunou PF, Kammoun H, Debrie AS, Mielcarek N, Locht C. 2010. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 28: 7047-7053. http://dx. doi. org/10. 1016/j. vaccine. 2010. 08. 017.
34. Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergström J, Ljungman M, Törner A, Wehlin L, Van Broekhoven A, Bosman F, Debrie AS, Mielcarek N, Locht C. 2014. A phase I clinical study of a live attenuated Bordetella pertussis vaccine-BPZE1; a single centre, doubleblind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One 9: e83449. http://dx. doi. org/10. 1371/journal. pone. 0083449.